Skip to main content
Clinical Trials/NCT04373226
NCT04373226TerminatedNot Applicable

Study of Arithmetic Abilities of Children With 22q11.2 Deletion Syndrome Aged From 4 to 11 Years Old

Hôpital le Vinatier2 sites in 1 country41 target enrollmentStarted: September 16, 2020Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Terminated
Sponsor
Enrollment
41
Locations
2
Primary Endpoint
Percentage of impaired scaled score

Study Overview

Brief Summary

The study ARITH22 will investigate the role of visuo-spatial attention on arithmetic abilities of children with 22q11.2 deletion syndrome.

Detailed Description

Children with 22q11.2 deletion syndrome often have arithmetic learning disability because of magnitude representation impairment. Previous works suggested that magnitude representation impairment could be a result of endogenous visuo-spatial attention dysfunction in 22q11.2DS. Nevertheless this relationship is still poor explored. The influence of visuo-spatial abilities on arithmetic achievement could also be modulated by developmental age. The study ARITH22 will test these hypotheses thanks to magnitude comparisons tasks, in children with 22q11.2 deletion syndrome and matched children without developmental disease.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Parallel
Primary Purpose
Basic Science
Masking
None

Eligibility Criteria

Ages
4 Years to 11 Years (Child)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Diagnosis of 22q11.2 deletion syndrome or no developmental disease
  • Aged from 4 to 11 years old
  • French language

Exclusion Criteria

  • Diagnosis of intellectual deficiency according to DSM 5 criteria
  • Drug prescribed for somatic condition that could influence cerebral functioning

Outcomes

Primary Outcomes

Percentage of impaired scaled score

Time Frame: single day

percentage of impaired scaled score at ZAREKI-R

Secondary Outcomes

  • Percentage of correct responses(single day)
  • Mean reaction time(single day)

Investigators

Sponsor
Hôpital le Vinatier
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials